Life Sciences
Former CEO Ed Cox tells the story of Dthera Sciences and outlines how the digital therapeutics landscape has shifted since his company's heyday.
According to FDA documents, the test is intended to help stop the spread of COVID-19 among Amazon employees.
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
The pilot study in north-east England will pioneer a personalised medicine approach.
The pair talk about the shift from traditional clinical trials based on drug research to digital innovations.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
The company's technology looks to reduce the burden on pathologists reviewing digital slides, while also serving as a safety net to reduce errors.
Along with the support of a Google Cloud-backed data platform, the partners will work to build and validate digital health programs for early intervention and engagement.
An initial pilot scheme will provide patients with access to local community pharmacists via the Push Doctor platform.
Asset Management Ventures' Skip Fleshman outlines COVID-19's impact on clinical trials and the resulting leap toward tech-enabled decentralized trials.